Pre-Surgery Inflammatory and Angiogenesis Biomarkers as Predictors of 12-Month Cancer-Related Distress: Results from the ColoCare Study.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
06 03 2023
06 03 2023
Historique:
received:
19
08
2022
revised:
18
11
2022
accepted:
27
12
2022
pubmed:
4
1
2023
medline:
8
3
2023
entrez:
3
1
2023
Statut:
ppublish
Résumé
Patients with colorectal cancer commonly suffer from complex psychological distress. Elevated distress may be linked to systemic biomarkers. We investigated associations of biomarkers of inflammation and angiogenesis with cancer-related distress (CTXD) score. N = 315 patients (stage I-IV) from 2 centers of the ColoCare Study were included: Huntsman Cancer Institute and University of Heidelberg. Biomarkers (e.g., IL6, VEGF-A, VEGF-D) were measured in serum collected pre-surgery and 12 months thereafter. The CTXD overall score and 4 subscales were collected 12 months after surgery and dichotomized to investigate biomarkers as predictors of distress 12 months after surgery; adjusted for age, sex, body mass index, tumor stage, center, and baseline levels of biomarkers. Doubling of IL6 predicted future increased risk of overall distress [odds ratio (OR), 1.20; 95% confidence interval (CI), 1.02-1.41; P = 0.03]. VEGF-A-predicted future increased risk of high family strain (VEGF-A: OR, 1.21; 95% CI, 1.01-1.44; P = 0.04) and VEGF-D was associated with medical and financial demands (OR, 1.34; 95% CI, 1.01-1.74; P = 0.03). This is the first study to show that systemic biomarkers are significantly associated with future CTXD score. Distress was not measured at baseline; we cannot rule out ongoing associations of inflammation and distress throughout treatment versus a direct effect of inflammation on distress. Nonetheless, these data add to evidence that biobehavioral processes interact and that systemic biomarkers are associated with cancer-related distress one year after surgery. Exercise and diet interventions that lower systemic cytokine levels may impact longer-term CTXD score and improve quality of life of patients with colorectal cancer.
Sections du résumé
BACKGROUND
Patients with colorectal cancer commonly suffer from complex psychological distress. Elevated distress may be linked to systemic biomarkers. We investigated associations of biomarkers of inflammation and angiogenesis with cancer-related distress (CTXD) score.
METHODS
N = 315 patients (stage I-IV) from 2 centers of the ColoCare Study were included: Huntsman Cancer Institute and University of Heidelberg. Biomarkers (e.g., IL6, VEGF-A, VEGF-D) were measured in serum collected pre-surgery and 12 months thereafter. The CTXD overall score and 4 subscales were collected 12 months after surgery and dichotomized to investigate biomarkers as predictors of distress 12 months after surgery; adjusted for age, sex, body mass index, tumor stage, center, and baseline levels of biomarkers.
RESULTS
Doubling of IL6 predicted future increased risk of overall distress [odds ratio (OR), 1.20; 95% confidence interval (CI), 1.02-1.41; P = 0.03]. VEGF-A-predicted future increased risk of high family strain (VEGF-A: OR, 1.21; 95% CI, 1.01-1.44; P = 0.04) and VEGF-D was associated with medical and financial demands (OR, 1.34; 95% CI, 1.01-1.74; P = 0.03).
CONCLUSIONS
This is the first study to show that systemic biomarkers are significantly associated with future CTXD score. Distress was not measured at baseline; we cannot rule out ongoing associations of inflammation and distress throughout treatment versus a direct effect of inflammation on distress. Nonetheless, these data add to evidence that biobehavioral processes interact and that systemic biomarkers are associated with cancer-related distress one year after surgery.
IMPACT
Exercise and diet interventions that lower systemic cytokine levels may impact longer-term CTXD score and improve quality of life of patients with colorectal cancer.
Identifiants
pubmed: 36595657
pii: 712706
doi: 10.1158/1055-9965.EPI-22-0882
pmc: PMC9991988
mid: NIHMS1862903
doi:
Substances chimiques
Vascular Endothelial Growth Factor D
0
Interleukin-6
0
Vascular Endothelial Growth Factor A
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
363-370Subventions
Organisme : NCI NIH HHS
ID : R03 CA270473
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA189184
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA206110
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207371
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA246659
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA254108
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215134
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA160684
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Informations de copyright
©2023 American Association for Cancer Research.
Références
Psychooncology. 2016 May;25(5):529-35
pubmed: 26130497
Mater Sociomed. 2012;24(2):112-20
pubmed: 23678317
Cancer. 2002 Aug 15;95(4):808-15
pubmed: 12209725
Psychooncology. 2017 Aug;26(8):1164-1171
pubmed: 27718504
Br J Psychiatry. 2010 Nov;197(5):372-7
pubmed: 21037214
Mol Psychiatry. 2020 Sep;25(9):2189-2199
pubmed: 31628416
Biomark Cancer. 2015 Oct 27;7(Suppl 1):13-9
pubmed: 26543385
Mol Psychiatry. 2020 Feb;25(2):321-338
pubmed: 31745238
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
J Hosp Palliat Nurs. 2012 Oct 1;14(7):462-468
pubmed: 23002383
Support Care Cancer. 2020 Sep;28(9):4361-4371
pubmed: 31916007
Adv Cancer Res. 2019;144:343-383
pubmed: 31349903
Eur J Cancer Care (Engl). 2019 Jul;28(4):e13055
pubmed: 31016796
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1251-1256
pubmed: 31590156
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Cancer. 2018 Aug 1;124(15):3240-3248
pubmed: 29757455
CA Cancer J Clin. 2015 Nov-Dec;65(6):428-55
pubmed: 26348643
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):951-61
pubmed: 25855626
Cancer. 2017 Oct 15;123(20):3882-3894
pubmed: 28833054
J Cancer Surviv. 2020 Jun;14(3):305-315
pubmed: 32166576
Sci Rep. 2021 Jan 26;11(1):2271
pubmed: 33500534
Mol Cancer. 2019 Sep 2;18(1):132
pubmed: 31477121
J Cancer Surviv. 2021 Dec;15(6):866-875
pubmed: 33420905
BMJ. 2017 Jan 25;356:j108
pubmed: 28122812
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):76-82
pubmed: 30333223
Am J Psychiatry. 2014 Dec 1;171(12):1278-86
pubmed: 25017001
Cancer. 2017 Apr 15;123(8):1416-1423
pubmed: 27893933
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1650-1660
pubmed: 35667092
Nat Med. 2006 Aug;12(8):939-44
pubmed: 16862152
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Brain Behav Immun. 2012 Mar;26(3):469-79
pubmed: 22251606
Transl Psychiatry. 2016 Sep 20;6(9):e895
pubmed: 27648917
Arthritis Rheum. 2010 Mar;62(3):683-93
pubmed: 20131240
J Cancer Surviv. 2022 Oct;16(5):1149-1164
pubmed: 34590205
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):591-601
pubmed: 30523039
J Clin Oncol. 2011 Sep 10;29(26):3517-22
pubmed: 21825266
Curr Neuropharmacol. 2018 Jan 30;16(2):176-209
pubmed: 28847294
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1229-1249
pubmed: 31590149
Cytokine. 2018 Apr;104:72-77
pubmed: 28969939